SCHEMBL5637404

SCHEMBL5637404

c1ccc(-c2cc3c4c(c2)[C@@H]2CNCC[C@@H]2N4CCCO3)cc1

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 6/20 0.48
HTR2A P28223 5/20 0.46
HTR2B P41595 3/20 0.46
HTR7 P34969 1/20 0.33
TMEM97 Q5BJF2 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
CHRNB4 P30926 2/20 0.32
CHRNA3 P32297 2/20 0.32
HTR6 P50406 2/20 0.32
KCNH2 Q12809 1/20 0.32
SLC18A3 Q16572 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5636261 0.89 HTR2C (0.52) HTR2CHTR2AHTR2BHTR6KCNH2
SCHEMBL5636401 0.87 HTR2C (0.45) HTR2CHTR2AHTR2BHTR7HTR6
SCHEMBL5635487 0.87 HTR2C (0.45) HTR2CHTR2AHTR2BHTR7
SCHEMBL5637062 0.85 HTR2C (0.43) HTR2CHTR2AHTR2BKCNH2
Hydrochloric Acid SCHEMBL5635163 0.85 HTR2C (0.65) HTR2CHTR2AHTR2BHTR6KCNH2
SCHEMBL5636676 0.85 HTR2C (0.44) HTR2CHTR2AHTR2BCHRNB4CHRNA3
SCHEMBL5635916 0.85 HTR2C (0.44) HTR2CHTR2AHTR2BHTR6KCNH2
SCHEMBL5637170 0.84 HTR2C (0.54) HTR2CHTR2AHTR2BKCNH2
SCHEMBL5636502 0.83 HTR2C (0.42) HTR2CHTR2AHTR2BCHRNB4CHRNA3
SCHEMBL5636282 0.83 HTR2C (0.46) HTR2CHTR2AHTR2BHTR6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE39679-E1 Substituted heterocycle fused gamma-carbolines BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-06-05 US disclosed
US-6713471-B1 SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-30 US disclosed